Chemical restraint means administering psychoactive drugs for discipline or convenience rather than to treat a medical symptom. Federal regulations require documented diagnosis, monitoring, and gradual dose reduction attempts for antipsychotic use.
Antipsychotic use in residents with dementia carries a boxed warning regarding increased mortality.
Alternative Names:
Chemical Restraint Claim, Inappropriate Psychotropic Use
Why it Matters?
Antipsychotic use in dementia is heavily scrutinized because the medications carry an increased mortality warning and are frequently prescribed without a qualifying diagnosis. The documentation requirements are specific: a supporting diagnosis, monitoring for adverse effects, and periodic attempts at gradual dose reduction. A record showing continued antipsychotic use without any of those elements supports both regulatory citation and an elder abuse theory.
Frequently Confused with
Related terms
Frequently asked questions
What documentation does antipsychotic use require?
Why is antipsychotic use in dementia scrutinized?
